Targeted Mono-Therapy for Newly Diagnosed Dilated Cardiomyopathy

In patients with Stage C heart failure with reduced ejection fraction (HFrEF), guidelines recommend initiating combined therapy with angiotensin-converting enzyme inhibition (ACEI) or angiotensin receptor blockade (ARB) and specific beta adrenergic receptor blockade (BARB).1 However, mono-therapy with BARB may be preferable to combined ACEI/ARB and BARB therapy in a subset of patients with newly diagnosed dilated cardiomyopathy.

Source: Journal of Cardiac Failure - May 30, 2019 Category: Cardiology Authors: Indranee Rajapreyar, Rohan Samson, Pierre Vladimir Ennezat, Thierry H Le Jemtel Source Type: research